Scholar Rock

Scholar Rock company information, Employees & Contact Information

Explore related pages

Related company profiles:

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/

Company Details

Employees
312
Founded
-
Address
301 Binney St, Cambridge,massachusetts 02142,united States
Phone
857-259-3860
Email
in****@****ock.com
Industry
Biotechnology
HQ
Cambridge, Massachusetts
Looking for a particular Scholar Rock employee's phone or email?

Scholar Rock Questions

News

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 - Business Wire

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 Business Wire

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference Yahoo Finance

426,250 Shares Worth of Options and RSUs: Scholar Rock's Major Employee Inducement Package Details - Stock Titan

426,250 Shares Worth of Options and RSUs: Scholar Rock's Major Employee Inducement Package Details Stock Titan

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs - ts2.tech

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs ts2.tech

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss - Yahoo Finance

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss Yahoo Finance

Scholar Rock's Breakthrough SMA Drug Shows Positive Phase 3 Results, FDA Fast-Tracks Review - Stock Titan

Scholar Rock's Breakthrough SMA Drug Shows Positive Phase 3 Results, FDA Fast-Tracks Review Stock Titan

Scholar Rock to Participate in Upcoming Investor Conferences - FinancialContent

Scholar Rock to Participate in Upcoming Investor Conferences FinancialContent

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth - Business Wire

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth Business Wire

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) - Yahoo Finance

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Yahoo Finance

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 - Business Wire

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 Business Wire

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 - Business Wire

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 Business Wire

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress - Business Wire

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress Business Wire

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress - Business Wire

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress Business Wire

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress - Business Wire

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress Business Wire

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition - Business Wire

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition Business Wire

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager - Business Wire

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager Business Wire

Scholar Rock Highlights 2025 Strategic Priorities - Business Wire

Scholar Rock Highlights 2025 Strategic Priorities Business Wire

FDA Hands Scholar Rock Complete Response Letter for Spinal Muscular Atrophy Agent Apitegromab - NeurologyLive

FDA Hands Scholar Rock Complete Response Letter for Spinal Muscular Atrophy Agent Apitegromab NeurologyLive

Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors - Scholar Rock

Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors Scholar Rock

Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer - Scholar Rock

Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer Scholar Rock

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin - Business Wire

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin Business Wire

Scholar Rock to Participate in Upcoming Investor Conferences - Business Wire

Scholar Rock to Participate in Upcoming Investor Conferences Business Wire

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer - Scholar Rock

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer Scholar Rock

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants Business Wire

FDA Delays First-Ever Muscle-Targeted SMA Treatment: Scholar Rock's Apitegromab Hits Manufacturing Hurdle - Stock Titan

FDA Delays First-Ever Muscle-Targeted SMA Treatment: Scholar Rock's Apitegromab Hits Manufacturing Hurdle Stock Titan

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Business Wire

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock - Business Wire

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock Business Wire

Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Business Wire

Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Business Wire

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity - Stock Titan

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity Stock Titan

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023 - Business Wire

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023 Business Wire

Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) - Stock Titan

Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) Stock Titan

Top Scholar Rock Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant